Only 1/25, 3/20, 2/27, and 1/16 patients had high CSF levels of T-tau, high levels of P-tau181, low levels of Aβ42, and low values of the Aβ42/Aβ40 ratio, respectively, with no patients displaying a typical CSF AD profile (i.e., both increased P-tau181 and decreased Aβ42). This evidence concerns the gene MAPT and Alzheimer disease.